大剂量吉西他滨膀胱灌注化疗对膀胱非肌层浸润性尿路上皮癌复发情况及不良反应的影响

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the influence of high-dose Gemcitabine intravesical infusion chemotherapy on the recurrence and adverse reactions of non-muscular invasive urothelial carcinoma of the bladder.Methods A total of 30 patients with non-muscular invasive urothelial carcinoma of the bladder who were admitted to the First People′s Hospital of Jiujiang City from July 2018 to June 2019 were selected as the research objects.According to the random number table method,they were divided into the control group(15 cases)and the study group(15 cases).The control group used regular dose Gemcitabine bladder perfusion local chemotherapy,and the study group used high-dose Gemcitabine intravesical infusion chemotherapy.The recurrence rate,recurrence time,and the total incidence rate of adverse reaction of the two groups were compared.Results The recurrence rate of the study group was lower than that of the control group,and the recurrence time of the study group was longer than that of the control group,the difference was statistically significant(P＜0.05).There was no statistically significant difference in the total incidence rate of adverse reaction between the two groups(P＞0.05).Conclusion High-dose Gemcitabine intravesical infusion chemotherapy for non-muscular invasive urothelial carcinoma of the bladder can reduce the recurrence rate and prolong the recurrence time to a certain extent,and have no significant increase in adverse reactions.

Key words： High-dose Gemcitabine Intravesical infusion chemotherapy Non-muscular invasive urothelial carcinoma of the bladder Recurrence rate

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WAN Bin
	ZHANG Wen-sheng
	DENG Xin-xi
	LI Xun-gang

Cite this article:

WAN Bin,ZHANG Wen-sheng,DENG Xin-xi, et al. Influence of high-dose Gemcitabine intravesical infusion chemotherapy on the recurrence and adverse reactions of non-muscular invasive urothelial carcinoma of the bladder[J]. 中国当代医药, 2021, 28(17): 103-105.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I17/103

[1]	蔡振，吴明震，孟宏乾.吉西他滨联合白细胞介素-2 灌注化疗对非肌层浸润性膀胱癌患者术后复发的预防效果[J].癌症进展，2020，18（12）：1274-1276，1289.
[2]	Berardinis ED，Antonini G，Peters GJ，et al.Intravesical administration of gemcitabine in superficial bladder cancer：a phase Ⅰstudy with pharmacodynamic evaluation[J].BJU Int，2015，93（4）：491-494.
[3]	孟涛，王纪科，刘锦波，等.吉西他滨与表柔比星序贯辅助治疗经尿道膀胱肿瘤切除术后非肌层浸润性膀胱癌的效果研究[J].中国肿瘤临床与康复，2020，27（6）：738-741.
[5]	杨成林，王尉，肖远松，等.肿瘤基底黏膜下吉西他滨溶液扩张辅助1470 nm 激光经尿道膀胱肿瘤整块切除术治疗非肌层浸润性膀胱癌[J].实用医学杂志，2019，35（1）：61-65.
[6]	豆振京，乔玉华，郭荣，等.吉西他滨灌注联合经尿道钬激光切除术对浅表性膀胱癌患者血清CXCL5 及尿NMP22水平的影响[J].河北医科大学学报，2020，41（7）：784-787，823.
[7]	许海涛.经尿道膀胱肿瘤电切术后吉西他滨、表柔比星序贯膀胱灌注治疗非肌层浸润性膀胱癌的临床效果[J].河南医学研究，2019，28（12）：2232-2233.
[4]	Junlong Z，Lan S，Lin Y，et al.TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA -LET/NF90/miR-145 Signaling Axis in Bladder Cancer[J].Theranostics，2017，7（12）：3053-3067.
[8]	许涛，李际桐，杨德君，等.吉西他滨膀胱灌注化疗的临床研究[J].实用药物与临床，2016，19（8）：949-951.
[9]	陈铁定，陈力，张鹏.膀胱肿瘤电切术后应用吉西他滨行膀胱灌注化疗的效果观察及对肿瘤标志物和生命质量的影响[J].中国医师进修杂志，2020，43（4）：364-367.
[10]	郭亮，马曜辉，管庆军，等.非肌层浸润性膀胱癌术后吉西他滨联合卡介苗膀胱灌注化疗的疗效及对免疫功能的影响[J].医药论坛杂志，2020，41（7）：89-93.
[11]	潘腾飞，武立新，刘祥鹏.吉西他滨联合舒泰凝胶在男性膀胱灌注化疗中的疗效观察[J].齐齐哈尔医学院学报，2020，41（5）：553-555.
[12]	秦克松，李金乾.膀胱癌行经尿道肿瘤电切术应用吉西他滨行膀胱灌注化疗的疗效观察[J].现代诊断与治疗，2019，30（3）：465-467.
[13]	蔡达潮，莫海金.膀胱癌患者术后行吡柔比星与吉西他滨膀胱灌注化疗的效果研究[J].中外医学研究，2019，17（6）：34-36.
[14]	王安莲，刘赟，胡世松，等.表柔比星与吉西他滨膀胱灌注化疗对浅表性膀胱尿路上皮癌术后复发及安全性的影响[J].国际泌尿系统杂志，2020，40（3）：478-481.
[15]	蔡琦，王战士，章伟，等.吉西他滨与吡柔比星术后即刻单次膀胱灌注化疗治疗低危膀胱癌疗效比较[J].浙江中西医结合杂志，2019，29（6）：500-502.
[16]	黄毅超，刘云军，陆小玲，等.调强放疗与同步吉西他滨化疗加吡柔比星热灌注化疗治疗老年晚期膀胱癌的近期疗效及预后分析[J].癌症进展，2018，16（2）：222-225，235.
[17]	郭学敬，王民，师磊，等.老年高危非肌层浸润性膀胱癌患者TURBt 后即刻吉西他滨膀胱热灌注与常温灌注化疗的临床观察[J].临床泌尿外科杂志，2018，33（10）：821-824.
[18]	陈伟，刘星，甄欣，等.吉西他滨膀胱灌注化疗联合体外深部热疗预防非肌层浸润性膀胱癌术后复发的临床效果及安全性[J].中国医药，2017，12（8）：1213-1216.